方盛制药：关于子公司获得药物临床试验批准通知书的公告

Core Viewpoint - Fangsheng Pharmaceutical's subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of its generic drug, RuLuGoli Tablets [1] Group 1 - The approval is a significant milestone for the company's drug development efforts [1] - The clinical trial approval indicates progress in the company's research and development pipeline [1]